Jpmorgan Chase & CO Lyra Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 109,405 shares of LYRA stock, worth $30,633. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109,405
Previous 33,170
229.83%
Holding current value
$30,633
Previous $173,000
293.06%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding LYRA
# of Institutions
82Shares Held
44.4MCall Options Held
300KPut Options Held
1.3K-
Perceptive Advisors LLC New York, NY12.8MShares$3.57 Million1.67% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.34MShares$1.21 Million0.01% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$789,8741.13% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$778,4735.45% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.74MShares$767,8880.04% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $8.91M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...